150
Participants
Start Date
March 31, 2015
Primary Completion Date
March 31, 2020
Study Completion Date
March 31, 2021
Aflibercept
"Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.~compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression."
Klinikum am Steinenberg Reutlingen, Reutlingen
University Medical Center Hamburg-Eppendorf, Hamburg
University of Ulm, Ulm
Collaborators (1)
Hubertus-Wald-Cancer Center Hamburg, Germany
UNKNOWN
Sanofi
INDUSTRY
Assign Data Management and Biostatistics GmbH
OTHER
University of Ulm
OTHER